SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Syndax Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.09+0.19 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Operating margin
-158.4%+4549.7 pts over 5 years
Net margin
-165.6%+4656.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +627.8% | – | +157.7% | +75.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 52.9% | -51.6% | -161.8% | |
| Return on assets | -44.7% | -40.2% | -45.5% | |
| Current ratio | 10.47 | 15.84 | 4.40 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | -30.3× | -45514.0× | |
| Capex to revenue | 21.4% | 0.0% | 0.1% | |
| Diluted shares | 15M | 41M | 87M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Syndax Pharmaceuticals generated $921.29M from operations and spent $316.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$921.29M
Used
$316.00K
Capital expenditure$316.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-165.6%
×Asset turnover0.27×
×Equity multiplier3.56×
=Return on equity, FY2025-161.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -165.6% | 0.27× | 3.56× | -161.8% |
| FY2024 | -1346.1% | 0.04× | 1.59× | -75.7% |
| FY2021 | 17.8% | 0.37× | 1.14× | 7.5% |
| FY2020 | -4822.5% | 0.01× | 1.28× | -51.6% |
| FY2019 | -3694.6% | 0.02× | 1.74× | -132.4% |
| FY2018 | -4875.5% | 0.01× | 1.41× | -94.0% |
| FY2017 | -2884.3% | 0.02× | 1.31× | -64.5% |
| FY2016 | -3645.2% | 0.01× | -1.18× | 52.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$285.42M
- Cash generatingOperating cash flow above zero-$322.98M
- Return on assets improvedROA up on the prior year-52.0% → -39.4%
- Earnings backed by cashOperating cash flow above net income-$322.98M vs -$285.42M
- Less leverageLong-term debt to assets fell45.7% → –
- Better liquidityCurrent ratio rose5.82 → 4.40
- No dilutionShare count did not rise86M → 87M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.24